Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researcher Uncovers Potential Key to Curing Tuberculosis

05.10.2009
Researchers at Iowa State University have identified an enzyme that helps make tuberculosis resistant to a human's natural defense system. Researchers have also found a method to possibly neutralize that enzyme, which may someday lead to a cure for tuberculosis.
Tuberculosis is caused by Mycobacterium tuberculosis and is a contagious disease that is on the rise, killing 1.5 to 2 million people worldwide annually.

Reuben Peters, associate professor in the department of biochemistry, biophysics and molecular biology, is leading the team of scientists from Iowa State; the University of Illinois, Urbana-Champaign; and Cornell University, Ithaca, New York, that is attempting to find ways to minimize the disease.

The group had their research published in the Aug. 28 issue of the Journal of Biological Chemistry, and their research is also scheduled to be the cover article in an upcoming issue of the Journal of the American Chemical Society.

When most infections are introduced into humans, the body defends itself with certain cells -- called macrophage cells -- that kill the invading micro-organisms. The macrophage cells engulf and destroy these microbes, such as the Mycobacterium tuberculosis.

Peters found that the mycobacterium tuberculosis produces a defensive molecule that prevents the macrophage cells from destroying them. Peters and his team named the defensive molecule edaxadiene.

Peters' next step was to try to find molecules that bind with the edaxadiene-producing enzymes from tuberculosis and neutralize them. This makes the tuberculosis cells unable to produce edaxadiene. Without edaxadiene, tuberculosis cells would have a reduced ability to resist being killed by the macrophage cells.

Peters thinks he may have already found one.

"We have inhibitors that bind tightly to one of the enzymes that make edaxadiene in a test tube," said Peters.

Finding an inhibitor that works outside of the test tube, and in humans, and is stable, and can be ingested safely by humans, and can help kill tuberculosis is a process that may take a decade.

But Peters sees a huge reward at the end of the process.

"This is the project where I tell my students, 'If we can make even just a 1 percent impact, we can save 15,000 - 20,000 lives a year.' That is really a significant contribution towards alleviating human suffering," said Peters.

Peters' group found the molecule by comparing the genetic makeup of tuberculosis - which kills humans - to the type that kills cattle but doesn't seem to have any effect on humans - Mycobacterium bovis.

"Their genetic sequences are more than 99.9 percent identical," said Peters.

"However, whereas, tuberculosis causes disease in humans, the bovis variety is much less infectious in humans, although it does cause disease in cattle."

One of the small differences in the genetic information between the two mycobacteria may hold the key to why one infects humans while the other does not.

"The bovis mycobacterium is missing only one nucleotide in the gene for one of the edaxadiene-producing enzymes, but that turns out to be very important as it prevents that enzyme from functioning," he said.

"The critical piece for this idea is that Mycobacterium bovis doesn't make edaxadiene, and doesn't affect humans much, whereas Mycobacterium tuberculosis does make edaxadiene and is infectious in humans," Peters said.

"We think this is the big difference between the two mycobacterium, mainly because this is the only difference I know of that seems to affect their infection process," he added.

"This work presents tantalizing evidence that edaxadiene helps the tuberculosis bacterium evade the body's defenses," said Warren Jones, who oversees enzymology grants at the National Institutes of Health's National Institute of General Medical Sciences, which funded the research. "By exploring ways to block the production of this molecule, Dr. Peters is pioneering a new approach for combating this deadly pathogen."

One of the hurdles that will confront Peters in finding human cures is that the effect of edaxadiene may be specific to humans, so the normal testing process may be difficult.

The normal testing sequence involves testing in the laboratory, then on smaller animals, then larger animals, and then to humans.

Since edaxadiene may be important for the ability of tuberculosis to infect humans, rather than animals, preventing production of edaxadiene by tuberculosis may not have much effect in animals, which will be challenging for the process of bringing a cure to drugstore shelves, according to Peters.

Peters added that he is eager to take on the next challenge in the fight against tuberculosis.

Peters' research team includes Francis Mann, doctoral student; Meimei Xu, associate scientist, both in ISU's department of biochemistry, biophysics and molecular biology; Sladjana Prisic, formerly a doctoral student in ISU's department of biochemistry, biophysics and molecular biology; Huayou Hu and Robert Coates, both from the University of Illinois; and David Russell from Cornell.

Reuben Peters | Newswise Science News
Further information:
http://www.iastate.edu

More articles from Life Sciences:

nachricht Designer cells: artificial enzyme can activate a gene switch
22.05.2018 | Universität Basel

nachricht Flow of cerebrospinal fluid regulates neural stem cell division
22.05.2018 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: LZH showcases laser material processing of tomorrow at the LASYS 2018

At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.

At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...

Im Focus: Self-illuminating pixels for a new display generation

There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?

At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...

Im Focus: Explanation for puzzling quantum oscillations has been found

So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics

Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...

Im Focus: Dozens of binaries from Milky Way's globular clusters could be detectable by LISA

Next-generation gravitational wave detector in space will complement LIGO on Earth

The historic first detection of gravitational waves from colliding black holes far outside our galaxy opened a new window to understanding the universe. A...

Im Focus: Entangled atoms shine in unison

A team led by Austrian experimental physicist Rainer Blatt has succeeded in characterizing the quantum entanglement of two spatially separated atoms by observing their light emission. This fundamental demonstration could lead to the development of highly sensitive optical gradiometers for the precise measurement of the gravitational field or the earth's magnetic field.

The age of quantum technology has long been heralded. Decades of research into the quantum world have led to the development of methods that make it possible...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Save the date: Forum European Neuroscience – 07-11 July 2018 in Berlin, Germany

02.05.2018 | Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

 
Latest News

Designer cells: artificial enzyme can activate a gene switch

22.05.2018 | Life Sciences

PR of MCC: Carbon removal from atmosphere unavoidable for 1.5 degree target

22.05.2018 | Earth Sciences

Achema 2018: New camera system monitors distillation and helps save energy

22.05.2018 | Trade Fair News

VideoLinks
Science & Research
Overview of more VideoLinks >>>